Patents Assigned to Teva Pharmaceuticals Australia Pty Ltd
  • Anti-CD47 combination therapy
    Patent number: 12258401
    Abstract: The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type I interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRP? receptor.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: March 25, 2025
    Assignee: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
    Inventors: Sarah Lee Pogue, David Scofield Wilson, Jr., Tetsuya Taura
  • Anti-CD47 combination therapy
    Patent number: 11618784
    Abstract: The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type 1 interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRP? receptor.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: April 4, 2023
    Assignee: Teva Pharmaceuticals Australia Pty Ltd.
    Inventors: Sarah Lee Pogue, David Scofield Wilson, Tetsuya Taura
  • Interferon alpha 2B variants
    Patent number: 11319356
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Combination of lenalidomide and polypeptide construct, and uses thereof
    Patent number: 11253591
    Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 22, 2022
    Assignee: Teva Pharmaceuticals Australia Pty Ltd.
    Inventors: Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 11117975
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 14, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 10981986
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: April 20, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Antibodies against TL1a and uses thereof
    Patent number: 10822422
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: November 3, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • Interferon alpha 2B variants
    Patent number: 10544199
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 28, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • ANTI-CD47 COMBINATION THERAPY
    Publication number: 20200010544
    Abstract: The present invention provides a combination therapy for treating a tumor in a subject. The combination comprises two elements. The first is a polypeptide construct comprising an attenuated Type 1 interferon (IFN) linked to an antibody which binds to a cell surface-associated antigen expressed on the tumour cell and comprising a functional Fc region. The second is a CD47 antagonist which inhibits the interaction CD47 with the SIRP? receptor.
    Type: Application
    Filed: July 19, 2017
    Publication date: January 9, 2020
    Applicant: TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
    Inventors: Sarah Lee POGUE, David Scofiled WILSON, JR., Tetsuya TAURA
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 9963515
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: May 8, 2018
    Assignee: Teva Pharmaceuticals Australia Pty Ltd.
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • Combination of lenalidomide and polypeptide construct, and uses thereof
    Patent number: 9636334
    Abstract: Methods for cancer treatment include administering to a cancer patient an anti-CD38 antibody-attenuated human IFN alpha-2b construct and lenalidomide or pomalidomide. Tumors that may be treated according to these methods include tumors which comprise CD-38 expressing tumor cells, including B-cell lymphoma, multiple myeloma, non-Hodgkin's lymphoma, chronic myelogenous leukemia, chronic lymphocytic leukemia, and acute lymphocytic leukemia.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: May 2, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Sarah L. Pogue, David S. Wilson, Anthony Gerard Doyle, Collette Jane Behrens
  • Fusions of antibodies to CD38 and attenuated interferon alpha
    Patent number: 9611322
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 4, 2017
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
  • Modified antibody with improved half-life
    Patent number: 9505826
    Abstract: The present invention relates to antibodies, immunoglobulin constructs or immunoglobulin IgG4 fusion proteins whose in vivo half-lives are increased by the combination of (i) a modified IgG4 Fc region or FcRn binding domain thereof and (ii) a modified IgG4 hinge region sequence.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: November 29, 2016
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David Wilson, Tetsuya Taura
  • Treatment of cancer involving mutated KRAS or BRAF genes
    Patent number: 8932588
    Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: January 13, 2015
    Assignee: Teva Pharmaceuticals Australia Pty. Ltd.
    Inventors: Norbert A. Kienzle, Anthony G. Doyle, Tony Rowe
  • Humanized antibodies with anti-tumor activity
    Patent number: 8901279
    Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: December 2, 2014
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
  • ANTIBODIES TO CD1d
    Publication number: 20140286957
    Abstract: Isolated antibodies or antigen binding portions thereof that bind to CD1d. These antibodies and antigen binding portions thereof have application in treatment of conditions involving NKT cell effector function.
    Type: Application
    Filed: April 10, 2014
    Publication date: September 25, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Jonathan Kannan Nambiar, Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Matthew Pollard, Huseyin Mustafa
  • ANTIBODIES AGAINST TL1a AND USES THEREOF
    Publication number: 20140255302
    Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
    Type: Application
    Filed: March 28, 2014
    Publication date: September 11, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
  • POLYPEPTIDE CONSTRUCTS AND USES THEREOF
    Publication number: 20140248238
    Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.
    Type: Application
    Filed: April 28, 2014
    Publication date: September 4, 2014
    Applicant: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: David S. Wilson, JR., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin